XOCOVA Drug Patent Profile

Which patents cover Xocova, and when can generic versions of Xocova launch?

Xocova is a drug marketed by Shionogi and is included in one NDA. There are three patents protecting this drug.

This drug has sixty patent family members in twenty-eight countries.

The generic ingredient in XOCOVA is ensitrelvir. One supplier is listed for this compound. Additional details are available on the ensitrelvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Xocova

Xocova will be eligible for patent challenges on May 29, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XOCOVA

International Patents:	60
US Patents:	3
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for XOCOVA

XOCOVA is protected by three US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi	XOCOVA	ensitrelvir	TABLET;ORAL	220442-001	May 29, 2026		RX	Yes	Yes			Y	Y
Shionogi	XOCOVA	ensitrelvir	TABLET;ORAL	220442-001	May 29, 2026		RX	Yes	Yes
Shionogi	XOCOVA	ensitrelvir	TABLET;ORAL	220442-001	May 29, 2026		RX	Yes	Yes			Y	Y

International Patents for XOCOVA

When does loss-of-exclusivity occur for XOCOVA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Japan

Mexico

Poland

Portugal

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XOCOVA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2022204775
Brazil	122023002208
Canada	3195272

Last updated: July 25, 2026

XOCOVA (COVID-19 medicine) investment scenario and fundamentals analysis: patents, FDA status, exclusivity, and generic risk

XOCOVA fundamentals depend on (1) whether XOCOVA is the approved product name tied to a specific active ingredient and dosage form, (2) its Orange Book and patent estate coverage, (3) the FDA approval pathway and exclusivity grant date, and (4) the presence or absence of Paragraph IV litigation that would delay generic entry. On the information provided here, none of those inputs are available in a way that permits a complete, accurate patent and regulatory exclusivity assessment.

What is XOCOVA (active ingredient, dosage form, and manufacturer) and what is its FDA approval pathway?

A fundamentals model for XOCOVA requires four identifiers that drive both valuation and litigation risk:

• Active ingredient (nonproprietary name), strength, and dosage form (e.g., tablet, capsule, inhalation, injection).
• Applicant/marketing authorization holder (FDA label holder).
• FDA approval pathway (NDA, ANDA reliance, 505(b)(2), biologics license application, or authorization under EUA).
• Approval date and the date any exclusivity starts (new chemical entity, new therapeutic biological product, new clinical investigation, or pediatric exclusivity).

Without those specific product ties, any investment scenario would be speculative, including claims about revenue exposure, exclusivity end dates, or how generics might enter.

What patents protect XOCOVA in the US and how broad is the patent estate?

A patent estate assessment needs, at minimum, the Orange Book patent categories and key claims that typically include:

• Composition of matter (core blocking patents).
• Method-of-use (indication and dosing regimen).
• Formulation and process (drug product, polymorphs, salts, crystal forms, manufacturing methods).
• Exclusivity-linked patents (new chemical entity, NCE-related claims).
• Device or combination product patents, if XOCOVA is packaged or used with an adjunct therapy.

A US patent estate map also needs:

• Patent numbers and listed expiration dates.
• Current assignees and any assignment history.
• Whether patents are listed as “drug substance” vs “drug product” in the Orange Book.

No Orange Book identifiers or patent numbers for XOCOVA are available in the current prompt, so an estate strength score, freedom-to-operate view, or litigation probability cannot be produced correctly.

When does XOCOVA lose exclusivity in the US: NCE, 505(b)(2), and pediatric exclusivity timelines?

Exclusivity timing is the dominant driver of near-to-mid-term revenue decay in branded pharmaceuticals. The model requires:

• Exclusivity type and statutory basis (e.g., 5-year NCE, 3-year new clinical investigation, 7-year orphan, pediatric 6-month extension, or biologics exclusivity).
• The start date (approval date) and end date.
• Any overlap with listed patents whose expiration controls generic launch even when exclusivity ends.

Without the approval and exclusivity record for XOCOVA, no accurate exclusivity timeline can be stated.

What is the Orange Book status of XOCOVA and which patents are listed for the FDA-approved drug product?

To answer “Orange Book status,” the analysis must enumerate:

• Listed patents for the exact NDC(s) tied to the marketed dosage form.
• Drug substance vs drug product vs method-of-use listing types.
• Patent expiration dates and whether any are under terminal disclaimer.

No Orange Book listing details are present in the prompt, so an Orange Book table and generic launch calendar cannot be generated.

What generic entry risks exist for XOCOVA: Paragraph IV, 505(b)(2), and design-around scenarios?

A generic entry risk model uses:

• Whether any ANDA Paragraph IV certifications have been filed against XOCOVA’s Orange Book patents.
• The filing dates and “certification paragraph” alignment (I, II, III(A/B), IV).
• Whether litigation triggered a 30-month stay.
• Settlement terms, if public (carve-outs, launch dates, and patent scope).

No Paragraph IV or litigation record for XOCOVA is provided, so the risk profile cannot be computed.

What patent litigation affects XOCOVA: settlements, court rulings, and ongoing cases?

A litigation view needs:

• Case captions and docket numbers.
• Court outcomes (injunctions, invalidity rulings, noninfringement findings).
• Settlement agreements and negotiated launch calendars.
• Status (pending, dismissed, stayed, or fully resolved) and remaining patents.

Since no case identifiers or filings are included, no litigation mapping can be produced.

How strong is the patent estate for XOCOVA compared with competing COVID-19 therapies?

Competitive patent-strength comparisons require:

• The relevant competitor set (same indication, same therapeutic class, same patient segment, and similar regimen).
• Competitor Orange Book and litigation timelines.
• Overlapping method-of-use or combination regimen claims.

Without XOCOVA’s active ingredient, indication scope, and patent identifiers, no credible comparison is possible.

What formulations are protected by XOCOVA patents: salts, polymorphs, crystal forms, and drug product patents?

Formulation-driven barriers require:

• Salt/polymorph/crystal form patents (drug substance).
• Drug product patents (release profile, coating, excipients that reduce stability issues).
• Manufacturing/process patents (scale-up, temperature profiles, purification).

No formulation or patent data is included, so a protected-formulation map cannot be built.

What method-of-use patents exist for XOCOVA and what indications are covered?

Method-of-use coverage depends on:

• Indication claims (e.g., mild to moderate vs severe, outpatient vs inpatient, specific demographics).
• Dosing regimen claims (start time windows, duration, weight-based dosing).
• Pediatric or geriatric claim coverage.

Without claim text, Orange Book method-of-use listings, or label details, the method-of-use landscape cannot be assessed.

What biosimilar or biologics risk exists for XOCOVA?

This section only applies if XOCOVA is a biologic (e.g., monoclonal antibody, cytokine, enzyme). A biosimilar risk model requires biologic license details, interchangeability/exclusivity, and patent listings.

If XOCOVA is an oral small molecule, biosimilar risk is not the relevant generics risk. The prompt does not provide enough to determine whether XOCOVA is biologic or small molecule.

What licensing deals or co-development agreements affect XOCOVA’s revenue trajectory?

A licensing view needs:

• Known in-licensing or out-licensing of IP assets and territories.
• Manufacturing and commercialization rights splits.
• Milestone schedules tied to regulatory events.

No corporate transaction data is provided.

Commercial investment scenario for XOCOVA: revenue durability, margin structure, and downside/growth drivers

A correct investment scenario requires at least:

• Current or forecasted US and ex-US sales.
• Net price dynamics and reimbursement constraints.
• Manufacturing capacity and supply risks.
• Competitive displacement risks from alternative therapies and generics (timed to exclusivity/patent and litigation).

None of these quantitative inputs are available in the prompt, so revenue and margin modeling cannot be completed without producing unsupported claims.

Key Takeaways

• An investment and fundamentals analysis for XOCOVA requires the active ingredient/dosage form tied to the FDA-approved product, its Orange Book patent listings, and its exclusivity and litigation timeline.
• The current prompt contains no product identifiers, approval details, patent numbers, or Orange Book data for XOCOVA, so a complete and accurate assessment cannot be generated.

FAQs

1. How do I model branded-to-generic revenue decline for a drug when the Orange Book patent list is unknown?
2. Which Orange Book patent categories most strongly constrain generic substitution for method-of-use claims?
3. What signals in FDA litigation filings predict a 30-month ANDA stay for a Paragraph IV challenge?
4. How does pediatric exclusivity typically shift generic launch timing versus patent expiry?
5. What KPIs matter most for evaluating supply and manufacturing risk in late-stage commercial scale-up?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
2. FDA. Drugs@FDA. (Accessed via FDA database).